Basic Information
| LncRNA/CircRNA Name | GAS5 |
| Synonyms | GAS5, NCRNA00030, SNHG2, ENST00000456293.5, GAS5-007 |
| Region | GRCh38_1:173863900-173868882 |
| Ensemble | ENSG00000234741 |
| Refseq | NR_002578 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | lung adenocarcinoma |
| ICD-0-3 | C34 |
| Methods | qPCR, RNAi etc. |
| Sample | cell lines (A549 and BEAS-2B) |
| Expression Pattern | differential expression |
| Function Description | Therefore, we assessed the functional consequences of GAS5 by designing short interfering RNAs (siRNAs) in lung adenocarcinoma. Great than 80% knockdown of GAS5 in lung adenocarcinoma cell line A549 resulted in decreased expression of its protein-coding targets CPS1 and AKR1C2 as predicted by our method. |
| Pubmed ID | 26336799 |
| Year | 2015 |
| Title | Integrative analysis reveals enhanced regulatory effects of human long intergenic non-coding RNAs in lung adenocarcinoma. |
External Links
| Links for GAS5 | GenBank HGNC NONCODE |
| Links for lung adenocarcinoma | OMIM COSMIC |